{
  "meta": {
    "title": "Inflammatory_Myositis_Igg4Rd_Amyloidosis",
    "url": "https://brainandscalpel.vercel.app/inflammatory-myositis-igg4rd-amyloidosis-90e20ae6.html",
    "scrapedAt": "2025-11-29T18:25:18.692Z"
  },
  "questions": [
    {
      "id": 19721,
      "choices": [
        {
          "id": 78845,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Systemic lupus erythematosus (SLE)</span></span></span></p>"
        },
        {
          "id": 78846,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Psoriasis</span></span></span></p>"
        },
        {
          "id": 78847,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dermatomyositis</span></span></span></p>"
        },
        {
          "id": 78848,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Scleroderma</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman presents with progressive muscle weakness, difficulty swallowing, and a persistent skin rash. She reports feeling tired and experiencing muscle aches. Physical examination reveals erythematous papules and plaques over the knuckles and elbows. Additionally, she has a purplish rash on her eyelids and periorbital edema. On examination patient&#39;s hands showing erythematous papules and plaques over the knuckles (as shown in the image below):</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/07/30/screenshot-2024-07-30-120241.png\" style=\"height:345px; width:300px\" /></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following is the most likely diagnosis?</span></span></span></p>",
      "unique_key": "Q2244005",
      "question_audio": null,
      "question_video": null,
      "map_id": 19528,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Dermatomyositis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical presentation of proximal muscle weakness, dysphagia, and characteristic skin findings (Gottron sign, heliotrope rash) strongly suggests dermatomyositis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Gottron sign:&nbsp;Erythematous papules and plaques over the extensor surfaces of joints (knuckles,&nbsp;elbows).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Heliotrope rash:&nbsp;Violaceous erythema on the eyelids and periorbital edema.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Systemic lupus erythematosus (SLE):</span></strong><span style=\"font-size:12.0pt\">&nbsp;While SLE can present with muscle weakness and skin rash,&nbsp;the pattern of skin involvement and presence of Gottron sign are more characteristic of dermatomyositis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Psoriasis:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Psoriasis typically presents with well-demarcated,&nbsp;silvery plaques on extensor surfaces,&nbsp;not the violaceous rash seen in this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Scleroderma:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Scleroderma is characterized by skin thickening and fibrosis,&nbsp;not the muscle weakness and specific rash seen in this case. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recognize the key clinical features of dermatomyositis, including Gottron&#39;s papules and heliotrope rash, as these are important for early diagnosis and prompt initiation of treatment.</span></span></span></p>",
      "correct_choice_id": 78847,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19722,
      "choices": [
        {
          "id": 78849,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">1%</span></span></span></p>"
        },
        {
          "id": 78850,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">5%</span></span></span></p>"
        },
        {
          "id": 78851,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">15%</span></span></span></p>"
        },
        {
          "id": 78852,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">30%</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In adult-onset dermatomyositis, the approximate risk of developing a malignancy within the first 2-3 years is:</span></span></p>",
      "unique_key": "Q9671944",
      "question_audio": null,
      "question_video": null,
      "map_id": 19529,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) 15%</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Studies have shown that adult-onset dermatomyositis is associated with a significantly increased risk of malignancy, particularly within the first few years after diagnosis. The risk is estimated to be around 15% within the first 2-3 years. It&#39;s crucial for clinicians to be aware of this association and consider appropriate screening measures for patients with adult-onset dermatomyositis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. 1%</span></strong><span style=\"font-size:12.0pt\">:&nbsp;This underestimates the risk of malignancy in adult-onset dermatomyositis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. 5%</span></strong><span style=\"font-size:12.0pt\">:&nbsp;While a significant risk,&nbsp;this is lower than the actual estimated risk.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. 30%</span></strong><span style=\"font-size:12.0pt\">:&nbsp;This overestimates the risk of malignancy in adult-onset dermatomyositis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Be aware of the increased risk of malignancy in adult-onset dermatomyositis and consider appropriate screening and surveillance for these patients.</span></span></span></p>",
      "correct_choice_id": 78851,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19723,
      "choices": [
        {
          "id": 78853,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Neutrophils</span></span></span></p>"
        },
        {
          "id": 78854,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Eosinophils</span></span></span></p>"
        },
        {
          "id": 78855,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Macrophages, B cells, and plasmacytoid dendritic cells (PDCs)</span></span></span></p>"
        },
        {
          "id": 78856,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lymphocytes and plasma cells</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The predominant inflammatory cell infiltrate in the muscle tissue of dermatomyositis patients is composed of:</span></span></p>",
      "unique_key": "Q9955335",
      "question_audio": null,
      "question_video": null,
      "map_id": 19530,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Macrophages, B cells, and plasmacytoid dendritic cells (PDCs)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The perivascular inflammatory infiltrate in dermatomyositis is characteristically composed of macrophages, B cells, and plasmacytoid dendritic cells.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Neutrophils</span></strong><span style=\"font-size:12.0pt\">:&nbsp;Not the predominant cell type</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Eosinophils</span></strong><span style=\"font-size:12.0pt\">:&nbsp;Not the predominant cell type</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Lymphocytes and plasma cells</span></strong><span style=\"font-size:12.0pt\">:&nbsp;While present,&nbsp;not the most prominent cell types</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Understanding the immune cell composition in dermatomyositis can help elucidate the underlying pathophysiology of the disease and guide the development of targeted therapies.</span></span></span></p>",
      "correct_choice_id": 78855,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19724,
      "choices": [
        {
          "id": 78857,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Early diagnosis and treatment</span></span></span></p>"
        },
        {
          "id": 78858,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Young age</span></span></span></p>"
        },
        {
          "id": 78859,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Presence of interstitial lung disease (ILD)</span></span></span></p>"
        },
        {
          "id": 78860,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Presence of anti-Mi-2 antibodies</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is NOT associated with a favorable prognosis in dermatomyositis?</span></span></p>",
      "unique_key": "Q5903736",
      "question_audio": null,
      "question_video": null,
      "map_id": 19531,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Presence of interstitial lung disease (ILD)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Presence of ILD:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Interstitial lung disease is a severe complication of dermatomyositis and is associated with increased morbidity and mortality.&nbsp;Its presence signifies a poorer prognosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Early diagnosis and treatment:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Early diagnosis and aggressive treatment can significantly improve outcomes in dermatomyositis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Young age:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Younger patients generally have a better prognosis than older patients.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Presence of anti-Mi-2 antibodies:</span></strong><span style=\"font-size:12.0pt\">&nbsp;The presence of anti-Mi-2 antibodies is often associated with a milder disease course and better response to treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recognizing the negative impact of ILD on the prognosis of dermatomyositis highlights the importance of early detection and aggressive management of this complication.</span></span></span></p>",
      "correct_choice_id": 78859,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19725,
      "choices": [
        {
          "id": 78861,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Asymmetric distal muscle weakness with rapid progression</span></span></span></p>"
        },
        {
          "id": 78862,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Symmetric proximal muscle weakness with gradual progression over weeks to months</span></span></span></p>"
        },
        {
          "id": 78863,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Painless muscle atrophy with sensory loss</span></span></span></p>"
        },
        {
          "id": 78864,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Focal muscle involvement with cranial nerve palsies</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Polymyositis (PM) is best characterized by which of the following clinical presentations?</span></span></p>",
      "unique_key": "Q7994659",
      "question_audio": null,
      "question_video": null,
      "map_id": 19532,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Symmetric proximal muscle weakness with gradual progression over weeks to months</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PM typically manifests with&nbsp;<strong>symmetric</strong>&nbsp;involvement of&nbsp;<strong>proximal</strong>&nbsp;muscles (those closer to the body&#39;s midline,&nbsp;like the shoulders and thighs).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The weakness usually&nbsp;<strong>progresses gradually</strong>&nbsp;over a period of&nbsp;<strong>weeks to months</strong>,&nbsp;not rapidly.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Pain</span></strong><span style=\"font-size:12.0pt\">&nbsp;and tenderness in the affected muscles are common.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Explanation</u>:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Asymmetric distal muscle weakness with rapid progression</span></strong><span style=\"font-size:12.0pt\">:&nbsp;This is more suggestive of other neuromuscular disorders like Guillain-Barr&eacute; syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Painless muscle atrophy with sensory loss</span></strong><span style=\"font-size:12.0pt\">:&nbsp;This pattern is more indicative of neuropathic conditions.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Focal muscle involvement with cranial nerve palsies</span></strong><span style=\"font-size:12.0pt\">:&nbsp;This might be seen in certain myopathies,&nbsp;but not the typical presentation of polymyositis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recognizing the classic presentation of PM is crucial for timely diagnosis and appropriate management. Distinguishing PM from other neuromuscular disorders with similar symptoms can guide further diagnostic testing and treatment decisions.</span></span></span></p>",
      "correct_choice_id": 78862,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19726,
      "choices": [
        {
          "id": 78865,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-PL-7</span></span></span></p>"
        },
        {
          "id": 78866,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-PL-12</span></span></span></p>"
        },
        {
          "id": 78867,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-OJ</span></span></span></p>"
        },
        {
          "id": 78868,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-Jo-1</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 42-year-old woman presents with progressive muscle weakness, particularly in her thighs and shoulders. She has difficulty climbing stairs and lifting objects. She also reports a persistent cough and shortness of breath on exertion. Additionally, she experiences joint pain and swelling in her hands and knees. Given the likely diagnosis, Which is the most common aminoacyl-tRNA synthetase (ARS) antibody found in this patients?</span></span></p>",
      "unique_key": "Q6511192",
      "question_audio": null,
      "question_video": null,
      "map_id": 19533,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Anti-Jo-1</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-Jo-1 antibodies are the most frequently encountered ARS antibodies in AS. These antibodies target the histidyl-tRNA synthetase enzyme and are associated with a classic clinical triad of myositis, interstitial lung disease, and arthritis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Anti-PL-7,&nbsp;B. Anti-PL-12&nbsp;</span></strong><span style=\"font-size:12.0pt\">and&nbsp;<strong>C. Anti-OJ</strong> are other ARS antibodies but are less common than anti-Jo-1.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recognizing the association between anti-Jo-1 antibodies and the clinical triad of myositis, ILD, and arthritis is crucial for accurate diagnosis and management of anti-synthetase syndrome, a subtype of inflammatory myopathy. This syndrome often requires aggressive immunosuppressive therapy to control both the muscle and lung disease.</span></span></span></p>",
      "correct_choice_id": 78868,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19727,
      "choices": [
        {
          "id": 78869,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">5 years </span></span></span></p>"
        },
        {
          "id": 78870,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">10 years </span></span></span></p>"
        },
        {
          "id": 78871,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">15 years </span></span></span></p>"
        },
        {
          "id": 78872,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">20 years</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In patients with Inclusion Body Myositis (IBM), the average time from symptom onset to requiring a wheelchair or scooter is approximately:</span></span></p>",
      "unique_key": "Q7627753",
      "question_audio": null,
      "question_video": null,
      "map_id": 19534,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) 15 years</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While IBM progresses slowly, the mean duration to significant mobility impairment requiring assistive devices like wheelchairs or scooters is around 15 years.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Understanding the natural history and progression of IBM is important for patient counselling and planning for future care needs.</span></span></span></p>",
      "correct_choice_id": 78871,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19728,
      "choices": [
        {
          "id": 78873,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Amyotrophic Lateral Sclerosis (ALS) </span></span></span></p>"
        },
        {
          "id": 78874,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Polymyositis (PM) </span></span></span></p>"
        },
        {
          "id": 78875,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inclusion Body Myositis (IBM) </span></span></span></p>"
        },
        {
          "id": 78876,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Myasthenia Gravis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 62-year-old man presents with gradual onset of difficulty gripping objects and rising from a chair. He also reports occasional choking when swallowing. Which of the following diagnoses is most likely?</span></span></p>",
      "unique_key": "Q1391781",
      "question_audio": null,
      "question_video": null,
      "map_id": 19535,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Inclusion Body Myositis (IBM)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of progressive hand weakness, difficulty with proximal leg muscles (rising from a chair), and dysphagia (choking when swallowing) points strongly towards IBM.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Amyotrophic Lateral Sclerosis (ALS):</span></strong><span style=\"font-size:12.0pt\"> While ALS can cause muscle weakness, it typically presents with a combination of upper and lower motor neuron signs (e.g., spasticity, hyperreflexia) and does not usually involve dysphagia early in the disease course.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Polymyositis (PM):</span></strong><span style=\"font-size:12.0pt\"> PM usually presents with symmetric proximal muscle weakness, rather than the asymmetric pattern of weakness often seen in IBM.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Myasthenia Gravis:</span></strong><span style=\"font-size:12.0pt\"> Myasthenia Gravis typically causes fluctuating muscle weakness that worsens with activity and improves with rest. It does not typically cause the pattern of muscle weakness seen in IBM.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recognizing the typical clinical presentation of IBM is essential for early diagnosis and appropriate management. IBM can be easily misdiagnosed as other neuromuscular disorders, so a high index of suspicion is necessary.</span></span></span></p>",
      "correct_choice_id": 78875,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19729,
      "choices": [
        {
          "id": 78877,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Congo red stain </span></span></span></p>"
        },
        {
          "id": 78878,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hematoxylin and eosin stain </span></span></span></p>"
        },
        {
          "id": 78879,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Periodic acid-Schiff (PAS) stain </span></span></span></p>"
        },
        {
          "id": 78880,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Immunostaining for p62</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following staining techniques is most sensitive for detecting inclusions in Inclusion Body Myositis?</span></span></p>",
      "unique_key": "Q7778850",
      "question_audio": null,
      "question_video": null,
      "map_id": 19536,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Immunostaining for p62</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Immunostaining for p62 is the most sensitive method for visualizing the amyloid-containing inclusions in IBM, especially those containing beta-sheet misfolded proteins.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Congo red stain:</span></strong><span style=\"font-size:12.0pt\"> While Congo red is used to detect amyloid deposits, it is not the most sensitive method for visualizing inclusions in IBM, especially in paraffin-embedded sections. The inclusions in IBM often do not stain well with Congo red due to their specific protein composition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hematoxylin and eosin (H&amp;E) stain:</span></strong><span style=\"font-size:12.0pt\"> H&amp;E is a standard stain for routine histological examination. It can visualize the general architecture of the muscle tissue and some inclusions, but it lacks the specificity and sensitivity of immunostaining for p62.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Periodic acid-Schiff (PAS) stain:</span></strong><span style=\"font-size:12.0pt\"> PAS stain is used to detect glycogen and other carbohydrates. While it can highlight some inclusions in IBM, it is not as specific or sensitive as p62 immunostaining for detecting the beta-sheet misfolded proteins that are characteristic of these inclusions.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Immunostaining for p62 is a valuable diagnostic tool for confirming the presence of characteristic inclusions in IBM muscle biopsies. It is more sensitive and specific than other staining techniques like Congo red, H&amp;E, or PAS.</span></span></span></p>",
      "correct_choice_id": 78880,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19730,
      "choices": [
        {
          "id": 78881,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Administer the standard dose of azathioprine </span></span></span></p>"
        },
        {
          "id": 78882,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Avoid azathioprine completely and use an alternative immunosuppressant </span></span></span></p>"
        },
        {
          "id": 78883,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Start azathioprine at a significantly reduced dose </span></span></span></p>"
        },
        {
          "id": 78884,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Begin with a standard dose and monitor closely for adverse effects</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">What is the recommended approach for patients with known TPMT deficiency who require azathioprine therapy?</span></span></p>",
      "unique_key": "Q5308719",
      "question_audio": null,
      "question_video": null,
      "map_id": 19537,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Start azathioprine at a significantly reduced dose</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients with TPMT deficiency can still be treated with azathioprine, but the dose needs to be significantly reduced (often 1/10th to 1/15th of the standard dose) to avoid life-threatening myelosuppression.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is crucial to test for TPMT deficiency before initiating azathioprine therapy. If deficiency is detected, the dose must be significantly reduced to avoid serious complications.</span></span></span></p>",
      "correct_choice_id": 78883,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19731,
      "choices": [
        {
          "id": 78885,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Polymyositis </span></span></span></p>"
        },
        {
          "id": 78886,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dermatomyositis </span></span></span></p>"
        },
        {
          "id": 78887,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Necrotizing Autoimmune Myopathy </span></span></span></p>"
        },
        {
          "id": 78888,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Myasthenia Gravis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 58-year-old woman presents with 6 months of progressive proximal muscle weakness, worsened after statin use. Examination reveals no rash. Labs show elevated creatine kinase (CK). Muscle biopsy demonstrates necrotic muscle fibers without significant inflammation. What is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q6619761",
      "question_audio": null,
      "question_video": null,
      "map_id": 19538,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Necrotizing Autoimmune Myopathy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Necrotizing Autoimmune Myopathy (NAM):</span></strong><span style=\"font-size:12.0pt\">&nbsp;Characterized by proximal muscle weakness,&nbsp;elevated CK,&nbsp;and muscle biopsy showing necrotic muscle fibers with minimal inflammation.&nbsp;Statin exposure is a known trigger for NAM.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Polymyositis:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Typically presents with symmetrical proximal weakness but would show inflammatory infiltrates on muscle biopsy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Dermatomyositis:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Similar to polymyositis but with characteristic skin findings (absent in this case).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Myasthenia Gravis:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Presents with fluctuating muscle weakness that worsens with activity and improves with rest.&nbsp;Muscle biopsy would not show necrosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Necrotizing autoimmune myopathy (NAM) is a rare subtype of autoimmune myopathies characterized by progressive muscle weakness, elevated creatine kinase, and muscle biopsy showing muscle fiber necrosis with minimal inflammation. Statin use can be a trigger. Treatment involves immunosuppressive medications.</span></span></span></p>",
      "correct_choice_id": 78887,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19732,
      "choices": [
        {
          "id": 78889,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Systemic lupus erythematosus (SLE) </span></span></span></p>"
        },
        {
          "id": 78890,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Polymyalgia rheumatica </span></span></span></p>"
        },
        {
          "id": 78891,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Steroid myopathy </span></span></span></p>"
        },
        {
          "id": 78892,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypothyroid myopathy</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 45-year-old woman with rheumatoid arthritis on corticosteroids for 6 months presents with new-onset proximal muscle weakness and fatigue. Physical examination confirms the muscle weakness. Which of the following is the most likely diagnosis?</span></span></span></p>",
      "unique_key": "Q7970827",
      "question_audio": null,
      "question_video": null,
      "map_id": 19539,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Steroid myopathy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Steroid myopathy:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Proximal muscle weakness is a common side effect of corticosteroid use,&nbsp;especially with longer durations and higher doses.&nbsp;This patient&#39;s history of recent corticosteroid use for rheumatoid arthritis makes steroid myopathy the most likely diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Systemic lupus erythematosus (SLE):</span></strong><span style=\"font-size:12.0pt\">&nbsp;While SLE can cause muscle weakness,&nbsp;it is usually accompanied by other systemic symptoms like rash,&nbsp;joint pain,&nbsp;and fever.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Polymyalgia rheumatica:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Typically affects older individuals and causes pain and stiffness in the shoulders and hips,&nbsp;not weakness.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Hypothyroid myopathy:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Can cause muscle weakness,&nbsp;but it is usually associated with other signs of hypothyroidism,&nbsp;such as fatigue,&nbsp;cold intolerance,&nbsp;and constipation.&nbsp;This patient&#39;s symptoms developed after starting corticosteroids,&nbsp;making steroid myopathy more likely.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Be aware of the potential for steroid myopathy in patients taking corticosteroids. It is important to monitor for muscle weakness and consider dose reduction or alternative therapies if this side effect develops.</span></span></span></p>",
      "correct_choice_id": 78891,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19733,
      "choices": [
        {
          "id": 78893,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic Fatigue Syndromes </span></span></span></p>"
        },
        {
          "id": 78894,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic Overlapping Pain Syndromes </span></span></span></p>"
        },
        {
          "id": 78895,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic Regional Pain Syndromes </span></span></span></p>"
        },
        {
          "id": 78896,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic Inflammatory Syndromes</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old woman presents with a 6-month history of widespread pain, fatigue, and difficulty sleeping. She also reports experiencing headaches, irritable bowel syndrome (IBS) symptoms, and anxiety. Physical examination is unremarkable except for multiple tender points. Given her symptoms and physical examination findings, which group of conditions is most likely to include her diagnosis?</span></span></p>",
      "unique_key": "Q1964180",
      "question_audio": null,
      "question_video": null,
      "map_id": 19540,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Chronic Overlapping Pain Syndromes</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation of widespread pain, fatigue, sleep disturbance, and multiple coexisting conditions like headaches and IBS aligns with the characteristics of Chronic Overlapping Pain Syndromes (COPS). These syndromes often share common underlying mechanisms and present with overlapping symptoms. Fibromyalgia is a classic example of a COPS condition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Chronic Fatigue Syndromes:</span></strong><span style=\"font-size:12.0pt\">&nbsp;While fatigue is a prominent feature in fibromyalgia,&nbsp;the presence of widespread pain and other symptoms differentiates it from chronic fatigue syndrome,&nbsp;which primarily focuses on debilitating fatigue.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Chronic Regional Pain Syndromes:</span></strong><span style=\"font-size:12.0pt\">&nbsp;These syndromes involve pain localized to a specific region of the body,&nbsp;unlike the widespread pain seen in this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Chronic Inflammatory Syndromes:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Although inflammation might play a role in some COPS conditions,&nbsp;it&#39;s not the defining characteristic.&nbsp;Fibromyalgia,&nbsp;for example,&nbsp;is not primarily an inflammatory disorder.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recognizing the concept of COPS is important for understanding the complex interplay of various chronic pain conditions and their potential shared pathophysiological mechanisms. This can help guide a more holistic approach to diagnosis and management.</span></span></span></p>",
      "correct_choice_id": 78894,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19734,
      "choices": [
        {
          "id": 78897,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">AA Amyloidosis </span></span></span></p>"
        },
        {
          "id": 78898,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">AL Amyloidosis </span></span></span></p>"
        },
        {
          "id": 78899,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A&beta; Amyloidosis </span></span></span></p>"
        },
        {
          "id": 78900,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ATTR Amyloidosis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old man with a history of rheumatoid arthritis presents with proteinuria and peripheral edema. Renal biopsy reveals amyloid deposits. Which type of amyloidosis is most likely in this patient?</span></span></p>",
      "unique_key": "Q7405733",
      "question_audio": null,
      "question_video": null,
      "map_id": 19541,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) AA Amyloidosis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">AA amyloidosis is secondary to chronic inflammatory conditions (like rheumatoid arthritis) and typically affects the kidneys.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. AL Amyloidosis</span></strong><span style=\"font-size:12.0pt\">: Associated with plasma cell dyscrasias.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. A&beta; Amyloidosis</span></strong><span style=\"font-size:12.0pt\">: Associated with Alzheimer&#39;s disease and deposits in the brain.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. ATTR Amyloidosis</span></strong><span style=\"font-size:12.0pt\">: Primarily affects the heart and nerves.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recognizing the association between chronic inflammatory diseases and AA amyloidosis is crucial for early diagnosis and intervention to prevent irreversible organ damage.</span></span></span></p>",
      "correct_choice_id": 78897,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19735,
      "choices": [
        {
          "id": 78901,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">AA Amyloidosis </span></span></span></p>"
        },
        {
          "id": 78902,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">AL Amyloidosis </span></span></span></p>"
        },
        {
          "id": 78903,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A&beta; Amyloidosis </span></span></span></p>"
        },
        {
          "id": 78904,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ATTR Amyloidosis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with long-standing multiple myeloma presents with nephrotic syndrome and macroglossia (enlarged tongue). Which of the following types of amyloidosis is most likely?</span></span></p>",
      "unique_key": "Q5995084",
      "question_audio": null,
      "question_video": null,
      "map_id": 19542,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) AL Amyloidosis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">AL amyloidosis is the most common type and is associated with plasma cell disorders like multiple myeloma. It often affects the kidneys, leading to nephrotic syndrome, and can cause macroglossia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. AA Amyloidosis:</span></strong><span style=\"font-size:12.0pt\"> This type is associated with chronic inflammatory conditions (like rheumatoid arthritis or Crohn&#39;s disease) and typically affects the kidneys, liver, and spleen. While it can cause nephrotic syndrome, macroglossia is less common.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. A&beta; Amyloidosis:</span></strong><span style=\"font-size:12.0pt\"> This type is associated with Alzheimer&#39;s disease and predominantly affects the brain. It does not typically cause systemic manifestations like nephrotic syndrome or macroglossia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. ATTR Amyloidosis:</span></strong><span style=\"font-size:12.0pt\"> This type can be hereditary or wild-type (age-related) and primarily affects the heart and nerves. It can also affect the kidneys and gastrointestinal tract, but macroglossia is not a typical feature.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Identifying AL amyloidosis as a potential complication of multiple myeloma is essential for prompt diagnosis and treatment to prevent organ damage and improve patient outcomes.</span></span></span></p>",
      "correct_choice_id": 78902,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19736,
      "choices": [
        {
          "id": 78905,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Serum protein electrophoresis </span></span></span></p>"
        },
        {
          "id": 78906,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Congo red staining of biopsy tissue </span></span></span></p>"
        },
        {
          "id": 78907,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bone marrow biopsy </span></span></span></p>"
        },
        {
          "id": 78908,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Echocardiogram</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which diagnostic test is considered the gold standard for confirming the presence of amyloid deposits in tissues?</span></span></p>",
      "unique_key": "Q5022246",
      "question_audio": null,
      "question_video": null,
      "map_id": 19543,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Congo red staining of biopsy tissue</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Congo red staining of tissue samples (often obtained from abdominal fat pad, rectum, or the affected organ) is the gold standard for diagnosing amyloidosis. It reveals apple-green birefringence under polarized light, characteristic of amyloid deposits.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Serum protein electrophoresis (SPEP):</span></strong><span style=\"font-size:12.0pt\"> SPEP can detect abnormal proteins in the blood, which may suggest amyloidosis. However, it does not directly visualize or confirm the presence of amyloid deposits in tissues.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Bone marrow biopsy:</span></strong><span style=\"font-size:12.0pt\"> Bone marrow biopsy is helpful in diagnosing AL amyloidosis, where amyloid deposits originate from light chains produced by plasma cells. However, it&#39;s not the gold standard for all types of amyloidosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Echocardiogram:</span></strong><span style=\"font-size:12.0pt\"> While an echocardiogram can reveal structural and functional abnormalities in the heart suggestive of amyloidosis (especially ATTR amyloidosis), it does not directly confirm the presence of amyloid deposits. A biopsy is still needed for definitive diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Understanding the role of Congo red staining in the diagnosis of amyloidosis is crucial for accurate identification and classification of this disease. It allows for confirmation of amyloid deposits in various tissues and helps distinguish different types of amyloidosis.</span></span></span></p>",
      "correct_choice_id": 78906,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19737,
      "choices": [
        {
          "id": 78909,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Complete reversal of heart failure symptoms </span></span></span></p>"
        },
        {
          "id": 78910,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Regression of cardiac hypertrophy </span></span></span></p>"
        },
        {
          "id": 78911,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stabilization of disease progression and improved quality of life </span></span></span></p>"
        },
        {
          "id": 78912,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cure of the underlying amyloidosis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old patient with ATTR amyloid cardiomyopathy and New York Heart Association (NYHA) class III heart failure is started on tafamidis. Which of the following is the most realistic expectation of treatment?</span></span></p>",
      "unique_key": "Q4287737",
      "question_audio": null,
      "question_video": null,
      "map_id": 19544,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Stabilization of disease progression and improved quality of life</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tafamidis is not a cure for ATTR amyloidosis. However, it can slow the progression of the disease, stabilize symptoms, and improve quality of life for patients with cardiomyopathy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Option A. Complete reversal of heart failure symptoms:&nbsp;</strong>Unlikely due to existing heart damage. </span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Regression of cardiac hypertrophy:</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Tafamidis doesn&#39;t reverse thickening. </span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Regression of cardiac hypertrophy:</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Tafamidis doesn&#39;t reverse thickening. </span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tafamidis is a valuable therapeutic option for ATTR amyloid cardiomyopathy, but it&#39;s important to understand its limitations. It&#39;s not a cure but can offer significant benefits in terms of slowing disease progression and improving quality of life.</span></span></span></p>",
      "correct_choice_id": 78911,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}